Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07263308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

Study acronym: ARISE-2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints revised (6)v6
  2. Trial sites expanded: 12 → 56 locationsv5
  3. Primary endpoint(s) modified
    • Eligibility criteria revised
    v4
  4. Study sites: 10 to 12
    • Start date changed from estimate of Dec 8, 2025 to Dec 18, 2025
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 10
    • Start date: Nov 27, 2025 to Dec 8, 2025
    • Secondary endpoints revised (6)
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective, multicenter, open-label, randomized controlled clinical trial. The investigators will apply albumin to the reperfusion treatment of patients with acute ischemic stroke in the anterior circulation. This study aims to verify the efficacy and safety of albumin combined with endovascular treatment in patients with anterior circulation acute ischemic stroke.
Trial Details
NCT Number NCT07263308
Lead Sponsor Capital Medical University
Conditions
(from sponsor)		 Acute Ischemic Stroke
Related terms Ischemic Stroke
Enrollment 1,192 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov